Publication | Closed Access
Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression
73
Citations
0
References
2005
Year
PathologyP-gp ExpressionCancer BiologyGliomaNeuroblastoma CellsMalignant BehaviorTumor BiologyNeuro-oncologyCancer Cell BiologyP-gp-mediated Multidrug-resistanceAnti-cancer AgentUkf-nb-3rvcr10 CellsRadiation OncologyMolecular OncologyCancer ResearchMedicineMycn AmplificationCancer GeneticsPharmacologyCell BiologyTumor MicroenvironmentTumor SuppressorOncology
Acquisition of P-gp-mediated multidrug-resistance does not always correlate with observed malignant behavior of NB. To characterize alterations accompanying development of multidrug-resistance in NB we established two neuroblastoma cell sublines resistant to vincristine (UKF-NB-3rVCR10) and doxorubicin (UKF-NB-3rDOX20). UKF-NB-3rVCR10 and UKF-NB-3rDOX20 overexpressed functional P-gp and developed an increased malignant phenotype: presented constitutive phosphorylation of AKT, resistance to gamma-irradiation, and had increased survival in serum-free medium. Inhibition of P-gp restored chemosensitivity but did not affect increased survival in serum-free medium and sensitivity to gamma-irradiation. Inhibition of AKT had no influence on chemoresistance but restored sensitivity to serum starvation. Both resistant cell lines acquired additional chromosomal changes. UKF-NB-3rVCR10 cells acquired a missense P53 mutation in exon 5, an increased MYCN amplification, an enhanced adhesion to endothelium, a decreased NCAM expression, a distinctly higher clonogenicity, and an increased in vivo tumorigenicity. We conclude that acquisition of increased malignant behavior in neuroblastoma occurs concomitantly with multidrug-resistance and is P-gp-independent.